CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine

Stock News07-19

CansinoBIO (06185) has announced that it has received an Acceptance Notice from China's National Medical Products Administration (NMPA).

The NMPA has accepted the company's supplemental application to expand the eligible age range for its ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier), known as MenQuad® (MCV4).

The application seeks to extend the age range from children aged 3 months to 6 years (83 months) to include individuals aged 3 months to 17 years.

MenQuad® is the first quadrivalent meningococcal conjugate vaccine in China. It received approval for marketing in December 2021, and its age range was previously expanded to children aged 3 months to 6 years (83 months) in February 2026.

The vaccine's launch has helped narrow the gap between China and developed nations in this field, addressing the previous lack of a high-end vaccine option.

MenQuad® provides a superior solution for preventing meningococcal disease in children aged 6 years and under in China.

Leveraging its innovative advantages, MenQuad® has demonstrated strong market performance and achieved a continuously growing market share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167018446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-19 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167018446","market":"nz","top_or_hot":-1,"title":"CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine","media":"Stock News","content":"<p><b>CansinoBIO</b> (<b>06185</b>) has announced that it has received an Acceptance Notice from China's National Medical Products Administration (NMPA).<br><br>The NMPA has accepted the company's supplemental application to expand the eligible age range for its ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier), known as MenQuad® (MCV4).<br><br>The application seeks to extend the age range from children aged 3 months to 6 years (83 months) to include individuals aged 3 months to 17 years.<br><br>MenQuad® is the first quadrivalent meningococcal conjugate vaccine in China. It received approval for marketing in December 2021, and its age range was previously expanded to children aged 3 months to 6 years (83 months) in February 2026.<br><br>The vaccine's launch has helped narrow the gap between China and developed nations in this field, addressing the previous lack of a high-end vaccine option.<br><br>MenQuad® provides a superior solution for preventing meningococcal disease in children aged 6 years and under in China.<br><br>Leveraging its innovative advantages, MenQuad® has demonstrated strong market performance and achieved a continuously growing market share.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-19 18:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CansinoBIO</b> (<b>06185</b>) has announced that it has received an Acceptance Notice from China's National Medical Products Administration (NMPA).<br><br>The NMPA has accepted the company's supplemental application to expand the eligible age range for its ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier), known as MenQuad® (MCV4).<br><br>The application seeks to extend the age range from children aged 3 months to 6 years (83 months) to include individuals aged 3 months to 17 years.<br><br>MenQuad® is the first quadrivalent meningococcal conjugate vaccine in China. It received approval for marketing in December 2021, and its age range was previously expanded to children aged 3 months to 6 years (83 months) in February 2026.<br><br>The vaccine's launch has helped narrow the gap between China and developed nations in this field, addressing the previous lack of a high-end vaccine option.<br><br>MenQuad® provides a superior solution for preventing meningococcal disease in children aged 6 years and under in China.<br><br>Leveraging its innovative advantages, MenQuad® has demonstrated strong market performance and achieved a continuously growing market share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1167018446","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167018446","pubTimestamp":1784456180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CansinoBIO (06185) has announced that it has received an Acceptance Notice from China's National Medical Products Administration (NMPA).The NMPA has accepted the company's supplemental application to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","06185":"康希诺生物","BK1191":"制药"},"translate_title":"康希诺生物获得NMPA批准延长MenQuad疫苗的使用年限","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CansinoBIO (06185) has announced that it has received an Acceptance Notice from China's National Medical Products Administration (NMPA).The NMPA has accepted the company's supplemental application to expand the eligible age range for its ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier), known as MenQuad® (MCV4).The application seeks to extend the age range from children aged 3 months to 6 years (83 months) to include individuals aged 3 months to 17 years.MenQuad® is the first quadrivalent meningococcal conjugate vaccine in China. It received approval for marketing in December 2021, and its age range was previously expanded to children aged 3 months to 6 years (83 months) in February 2026.The vaccine's launch has helped narrow the gap between China and developed nations in this field, addressing the previous lack of a high-end vaccine option.MenQuad® provides a superior solution for preventing meningococcal disease in children aged 6 years and under in China.Leveraging its innovative advantages, MenQuad® has demonstrated strong market performance and achieved a continuously growing market share.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167018446","isCrawlerRequest":true}